Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

    Interim Management Statement - 3 months to 31 December 2012 (unaudited)    

Worldwide Healthcare Trust PLC invests in the global healthcare sector with the
objective of achieving a high level of capital growth. In order to achieve its 
investment objective, the Company invests worldwide in a diversified portfolio 
of shares in pharmaceutical and biotechnology companies and related securities.
The Company uses gearing and derivative transactions to mitigate risk and also 
                               enhance returns.                                

During the 3 month period ended 31 December 2012 the Company's fully diluted
net asset value per share total return was -2.3%. The Company's share price
total return and the return from the Company's benchmark, the MSCI World Health
Care Index measured in sterling terms on a total return basis, were both
slightly positive (+0.2%). During the period, exposure to North America and
Europe was increased while exposure to Asia was reduced. At the stock level,
percentage holdings in Roche and Sanofi rose while those in Merck and
Mitsubishi Tanabe Pharma fell.

During the three-month period no shares were repurchased by the Company and
9,946 new shares were issued, as a result of holders of subscription shares
exercising their subscription rights, raising £70,000 of additional funds for
the Company.

Since the period end, to 1 February 2013, no shares were bought back by the
Company. However, 50,000 shares were reissued from treasury, at a discount of
4.89% to the Company's cum income net asset value per share, this being a
narrower discount than that at which the shares had been repurchased by the
Company. This raised £424,000 of additional funds for the Company. In addition,
33,336 new shares were allotted on 1 February 2013, as a result of holders of
subscription shares exercising their subscription rights, raising £233,000 of
additional funds for the Company. As at 1 February 2013 there were 45,434,746
shares in issue excluding 328,408 shares held in treasury. There were also
2,389,926 subscription shares in issue.

In the period from 31 December 2012 to 31 January 2013, the Company's fully
diluted net asset value per share total return was 9.6%, in line with the
Company's benchmark. The share price total return was 7.0%.

A first interim dividend of 7.0p per share, for the year to 31 March 2013, was
paid on 11 January 2013 to shareholders on the register of members on 14
December 2012. The associated ex-dividend date was 12 December 2012.

During the period Mr Doug McCutcheon joined the Board. Based in Canada, and a
former head of UBS Healthcare Investment Banking for Europe, the Middle East
and Africa, he has over 25 years' experience as an investment banker, 16 of
which were spent specialising in the healthcare sector.

Trust Characteristics

                                   31 December 2012      30 September 2012     
                                                                               
Number of holdings                        60                       57          
                                                                               
Net assets (£m)                         405.5                    419.1         
                                                                               
Indicative yield                         1.8%                     2.0%         
                                                                               
Gearing (AIC basis)                      102                      103          
                                                                               
Share price (p)                         855.00                   860.50        
                                                                               
NAV (p) -undiluted (ex                  894.23                   924.30        
income)                                                                        
                                                                               
NAV (p) diluted: sub shares             884.33                   912.82        
(ex income)                                                                    
                                                                               
NAV (p) - fully diluted for             884.10                   912.41        
sub shares                                                                     
                                                                               
and treasury shares (ex                                                        
income)                                                                        
                                                                               
(Discount)/premium                      (4.4%)                   (6.9%)        
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted -             (3.3%)                   (5.7%)        
sub shares)                                                                    
                                                                               
(Discount)/premium (fully               (3.3%)                   (5.7%)        
diluted)                                                                       
                                                                               
Subscription share price (p)            186.00                   179.00        

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                      % of            
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2012      at 30 September 2012    
                                                                               
Roche                                 9.3                       8.4            
                                                                               
Sanofi                                4.7                       4.1            
                                                                               
Pfizer                                4.6                       4.4            
                                                                               
Gilead Sciences                       4.1                       4.0            
                                                                               
Abbott Laboratories                   3.9                       4.0            
                                                                               
Merck & Co                            3.7                       5.2            
                                                                               
HCA                                   2.6                       2.2            
                                                                               
Bristol-Myers Squibb                  2.2                       2.2            
                                                                               
Onyx Pharmaceuticals                  2.2                       2.5            
                                                                               
GlaxoSmithKline                       2.1                       2.2            
                                                                               
                                     39.4                      39.2            

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2012       at 30 September 2012   
                                                                               
Large capitalisation                 64.2                       63.6           
                                                                               
Small capitalisation                 35.8                       36.4           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                             at 31 December 2012        at 30 September 2012   
                                                                               
North America                        58.7                       57.1           
                                                                               
Europe                               21.1                       20.2           
                                                                               
Asia                                 8.9                        11.9           
                                                                               
Emerging Markets                     11.3                       10.8           
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance to 31 December 2012

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +0.2%           +20.3%          +48.0%          +86.8%         
                                                                               
NAV Fully       -2.3%           +14.4%          +44.5%          +80.5%         
diluted                                                                        
                                                                               
Benchmark*      +0.2%           +12.2%          +35.2%          +68.3%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Thomson Reuters and Bloomberg

*Benchmark - With effect from 1 October 2010, the performance of the Company is
measured against the MSCI World Health Care Index on a total return, sterling
adjusted basis. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index measured in sterling
terms on a total return basis. Historic data, therefore, consists of a blended
figure containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the Company's website www.worldwidewh.com and
on the TrustNet website at www.trustnet.com

Identification Codes:

Ordinary Shares

SEDOL- 0338530

ISIN - GB0003385308

Bloomberg - WWH LN

EPIC - WWH

Subscription Shares

SEDOL - B3VMCB0

ISIN - GB00B3VMCB07

Bloomberg - WWHS LN

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

1 February 2013